Clinical Study
Are Breast Cancer Molecular Classes Predictive of Survival in Patients with Long Follow-Up?
Table 3
General clinical-pathological parameters and immunohistochemistry results of breast tumors according to molecular classification (
).
| | Features | Luminal A (140) n (%) | Luminal B (102) n (%) | HER2 (24) n (%) | Triple negative (38) n (%) | P |
| | Age at diagnosis, years | 47.4 | 46.6 | 45.9 | 46.5 | 0.7 | | (range) | (30–55) | (30–55) | (28–55) | (26–55) | | Age, years | | | | | | | ≤35 | 4 (3) | 10 (10) | 4 (17) | 3 (8) | 0.04* | | >35 | 136 (97) | 92 (90) | 20 (83) | 35 (92) | | Histology | | | | | | | Ductal | 110 (79) | 89 (87) | 23 (96) | 30 (79) | 0.002* | | Lobular | 16 (11) | 10 (10) | 1 (4) | 1 (3) | | Medullary | 0 | 0 | 0 | 6 (16) | | Mucinous | 3 (2) | 3 (3) | 0 | 1 (3) | | Tubular | 11 (8) | 0 | 0 | 0 | | Grade | | | | | | | 1 | 34 (25) | 5 (4) | 0 | 0 | 0.000* | | 2 | 77 (55) | 49 (48) | 9 (37) | 9 (24) | | 3 | 29 (20) | 48 (48) | 15 (63) | 297 (76) | | Tumor size, cm | | | | | | | ≤2 | 95 (68) | 50 (49) | 12 (50) | 23 (62) | 0.1 | | 2–5 | 39 (28) | 44 (43) | 11 (46) | 12 (32) | | ≥5 | 5 (4) | 7 (7) | 1 (4) | 2 (5) | | Missing | 1 | 1 | 0 | 1 | | Lymph node involvement | | | | | | | No | 98 (70) | 28 (27) | 5 (21) | 19 (50) | 0.000* | | Yes | 42 (30) | 74 (73) | 19 (79) | 19 (50) | | Lymph nodes | | | | | | | 1–3 | 28 (67) | 51 (69) | 10 (53) | 8 (44) | 0.1 | | ≥4 | 14 (33) | 23 (31) | 9 (47) | 10 (56) | | Missing | 0 | 0 | 0 | 1 | | Stage | | | | | | | I | 71 (51) | 17 (16) | 4 (16) | 14 (38) | 0.000* | | II | 48 (34) | 55 (54) | 9 (38) | 13 (35) | | III | 21 (15) | 30 (30) | 11 (46) | 10 (27) | | Missing | 0 | 0 | 0 | 1 | | Recurrence | | | | | | | No | 78 (58) | 43 (45) | 5 (23) | 16 (42) | 0.02* | | Yes | 56 (42) | 53 (55) | 17 (77) | 21 (55) | | Missing | 6 | 6 | 2 | 1 | | Status | | | | | | | BC specific death | 45 (32) | 48 (47) | 14 (58) | 21 (55) | | | ER | | | | | | | Negative | 0 | 0 | 24 (100) | 38 (100) | | | Positive | 140 (100) | 102 (100) | 0 | 0 | | | PR | | | | | | | Negative | 6 (4) | 13 (13) | 24 (100) | 38 (100) | | | Positive | 134 (96) | 89 (87) | 0 | 0 | | | HER2 | | | | | | | Negative | 140 (100) | 65 (64) | 0 | 38 (100) | | | Positive | 0 | 37 (36) | 24 (100) | 0 | | | Ki67 | | | | | | | <14% | 140 (100) | 6 (6) | 4 (17) | 6 (16) | | | ≥14% | 0 | 96 (94) | 20 (83) | 32 (84) | | | CK8 | | | | | | | Negative | 0 | 0 | 5 (21) | 24 (63) | | | Positive | 140 (100) | 102 (100) | 19 (79) | 14 (37) | | | CK5/6 | | | | | | | Negative | 125 (89) | 89 (87) | 19 (79) | 2 (5) | | | Positive | 15 (11) | 13 (13) | 5 (21) | 36 (95) | | | Vimentin | | | | | | | Negative | 107 (76) | 65 (64) | 14 (58) | 10 (26) | 0.000* | | Positive | 33 (24) | 37 (36) | 10 (42) | 28 (74) | | AR | | | | | | | Negative | 19 (21) | 20 (26) | 14 (70) | 26 (100) | 0.000* | | Positive | 73 (79) | 57 (74) | 6 (30) | 0 |
|
|
ER: estrogen receptor, PR: progesterone receptor, HER2: human epidermal growth factor receptor, CK8: cytokeratin 8, CK5/6: cytokeratin 5/6, AR: androgen receptor. *Statistically significant data.
|
